{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:24:02Z","timestamp":1791300242136,"version":"4.1.0"},"reference-count":26,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We have developed and previously reported on a therapeutic vaccination strategy for indolent B-cell lymphoma that combines local radiation to enhance tumor immunogenicity with the injection into the tumor of a TLR9 agonist. As a result, antitumor CD8+ T cells are induced, and systemic tumor regression was documented. Because the vaccination occurs in situ, there is no need to manufacture a vaccine product. We have now explored this strategy in a second disease: mycosis fungoides (MF). We treated 15 patients. Clinical responses were assessed at the distant, untreated sites as a measure of systemic antitumor activity. Five clinically meaningful responses were observed. The procedure was well tolerated and adverse effects consisted mostly of mild and transient injection site or flu-like symptoms. The immunized sites showed a significant reduction of CD25+, Foxp3+ T cells that could be either MF cells or tissue regulatory T cells and a similar reduction in S100+, CD1a+ dendritic cells. There was a trend toward greater reduction of CD25+ T cells and skin dendritic cells in clinical responders versus nonresponders. Our in situ vaccination strategy is feasible also in MF and the clinical responses that occurred in a subset of patients warrant further study with modifications to augment these therapeutic effects. This study is registered at www.clinicaltrials.gov as NCT00226993.<\/jats:p>","DOI":"10.1182\/blood-2011-05-355222","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T23:46:31Z","timestamp":1320191191000},"page":"355-363","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":193,"title":["In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study"],"prefix":"10.1182","volume":"119","author":[{"given":"Youn H.","family":"Kim","sequence":"first","affiliation":[{"name":"Departments of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dita","family":"Gratzinger","sequence":"additional","affiliation":[{"name":"Pathology, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Harrison","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra K.","family":"Czerwinski","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of California\u2013San Francisco, San Francisco;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Morales","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon","family":"Xing","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Navi","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Tibshirani","sequence":"additional","affiliation":[{"name":"Department of Health Research Policy and Statistics, Stanford University, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi","family":"Lingala","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Hoppe","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Levy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111814175443800_B1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas.","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2019111814175443800_B2","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1172\/JCI24826","article-title":"Immunopathogenesis and therapy of cutaneous T-cell lymphoma.","volume":"115","author":"Kim","year":"2005","journal-title":"J Clin Invest"},{"issue":"9616","key":"2019111814175443800_B3","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(08)60420-1","article-title":"Mycosis fungoides and Sezary syndrome.","volume":"371","author":"Hwang","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"2019111814175443800_B4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.6004\/jnccn.2008.0033","article-title":"Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach.","volume":"6","author":"Horwitz","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"2019111814175443800_B5","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2006-12-062877","article-title":"Clinical efficacy of zanolimumab (HuMax-CD4): two phase II studies in refractory cutaneous T-cell lymphoma.","volume":"109","author":"Kim","year":"2007","journal-title":"Blood"},{"key":"2019111814175443800_B6","doi-asserted-by":"crossref","first-page":"424a","DOI":"10.1182\/blood.V116.21.962.962","article-title":"Results of a phase 1\/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4) in CTCL patients [abstract].","volume":"116","author":"Duvic","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2019111814175443800_B7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/10428190600581419","article-title":"Transimmunization for cutaneous T-cell lymphoma: a phase I study.","volume":"47","author":"Girardi","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2019111814175443800_B8","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells.","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"2019111814175443800_B9","first-page":"s56","article-title":"Patient-specific dendritic cell immunization against tumor in Sezary syndrome.","volume":"130","author":"Geskin","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"7","key":"2019111814175443800_B10","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells.","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2019111814175443800_B11","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy.","volume":"117","author":"Krieg","year":"2007","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111814175443800_B12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a toll-like receptor 9 agonist, PF-3512676 (CPG7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.","volume":"63","author":"Kim","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2019111814175443800_B13","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.179.4.2493","article-title":"Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.","volume":"179","author":"Li","year":"2007","journal-title":"J Immunol"},{"issue":"28","key":"2019111814175443800_B14","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression.","volume":"28","author":"Brody","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111814175443800_B15","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical endpoints and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer (EORTC).","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111814175443800_B16","first-page":"2212","article-title":"Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases.","volume":"95","author":"Vergier","year":"2000","journal-title":"Blood"},{"issue":"4","key":"2019111814175443800_B17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CJI.0b013e318163628c","article-title":"Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy.","volume":"31","author":"Teitz-Tennenbaum","year":"2008","journal-title":"J Immunother"},{"issue":"6","key":"2019111814175443800_B18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1667\/RR1600.1","article-title":"Migration of skin dendritic cells in response to ionizing radiation exposure.","volume":"171","author":"Cummings","year":"2009","journal-title":"Radiat Res"},{"issue":"1","key":"2019111814175443800_B19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death.","volume":"13","author":"Obeid","year":"2007","journal-title":"Nature Med"},{"issue":"3","key":"2019111814175443800_B20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership.","volume":"63","author":"Demaria","year":"2005","journal-title":"Int J Rad Oncol Biol Phys"},{"issue":"3","key":"2019111814175443800_B21","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.25011\/cim.v31i3.3472","article-title":"Potentiation of the immunotherapeutic effect of autologous dendritic cells by pretreating hepatocellular carcinoma with low-dose radiation.","volume":"31","author":"Lin","year":"2008","journal-title":"Clin Invest Med"},{"issue":"4","key":"2019111814175443800_B22","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1182\/blood-2004-06-2181","article-title":"Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.","volume":"105","author":"Berger","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111814175443800_B23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nri1498","article-title":"Mechanisms and functional significance of tumor-induced dendritic cell defects.","volume":"4","author":"Gabrilovich","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2019111814175443800_B24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.molimm.2008.09.015","article-title":"Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine.","volume":"46","author":"Gigante","year":"2009","journal-title":"Mol Immunol"},{"issue":"19","key":"2019111814175443800_B25","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1158\/1078-0432.CCR-09-1254","article-title":"Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.","volume":"15","author":"Ribas","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111814175443800_B26","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2007-06-094615","article-title":"IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.","volume":"110","author":"Litzinger","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/2\/355\/1496910\/zh800212000355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/2\/355\/1496910\/zh800212000355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:18:05Z","timestamp":1574086685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/2\/355\/105495\/In-situ-vaccination-against-mycosis-fungoides-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,1,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-355222","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}